We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Request Information

To request more information about this product, please complete the form below.

D614G : SARS-CoV-2 S1 Variant content piece image

Product
Advertisement

D614G : SARS-CoV-2 S1 Variant

D614G : SARS-CoV-2 S1 Variant

A recent study from Los Alamos National Laboratory has identified a major mutation on SARS-CoV-2 Spike. This D614G mutation has rapidly become dominant in these regions, suggesting this mutation may make the SARS-CoV-2 virus more transmissive. It's critical to understand the biology of this variant, particularly in the context of vaccine and drug design.

Sino Biological has developed a recombinant S1 protein with a D614G mutation (40591-V08H3). The recombinant 614G variant demonstrated an ACE2 binding activity.

In addition to the D614G mutation, several other mutations are also identified. Some of them are believed to enhance S1's ability to bind with ACE2. Sino Biological has developed a panel of mutated RBD proteins to facilitate the study of these variants.

Full List of SARS-CoV-2 Antigens


About Sino Biological
Sino Biological, an international reagent supplier and service provider, specializes in recombinant protein production and antibody development. All of the products are independently developed and produced, including recombinant proteins, antibodies and cDNA. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements and offers pre-clinical production technology services for monoclonal antibody drug candidates.
Interested in seeing more content from Sino Biological?
Discover all their latest news, webinars, products and more by clicking the link below.